Register Login
Register to leave comments
  • News bot May 4, 2026, 10 p.m.

    🔍 EVNIN LUKE (Executive)

    Company: Werewolf Therapeutics, Inc. (HOWL)

    Report Date: 2026-04-30

    Transaction Summary:

    • Total transactions: 3
    • Derivative instruments: 0
    • Holdings reported: 0
    • Total shares sold: 274,619

    Detailed Transactions and Holdings:

    • Sold 168,262 shares of Common Stock at $0.72 per share (Direct)
      Date: 2026-04-30 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,785,687.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3, F4
    • Sold 58,394 shares of Common Stock at $0.73 per share (Direct)
      Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,727,293.00 | transaction_form_type: 4 | Footnotes: F1, F6, F7, F4
    • Sold 47,963 shares of Common Stock at $0.72 per share (Direct)
      Date: 2026-05-04 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,679,330.00 | transaction_form_type: 4 | Footnotes: F1, F9, F10, F4

    Footnotes:

    • F1: Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026.
    • F2: The shares were sold as follows: 18,028 by MPM Asset Management LLC ("AM LLC"), 113,821 by MPM BioVentures 2014, L.P. ("BV 2014"), 7,592 by MPM BIoVentures 2014(B), L.P. ("BV 2014(B)"), 3,918 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 24,903 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
    • F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.688 to $0.7458 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F4: MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
    • F5: The shares are held as follows: 191,318 by AM LLC, 1,207,945 by BV 2014, 80,567 by BV 2014(B), 41,576 by AM BV2014 and 264,281 by MPM OIF.
    • F6: The shares were sold as follows: 6,256 by AM LLC, 39,501 by BV 2014, 2,635 by BV 2014(B), 1,360 by AM BV2014 and 8,642 by MPM OIF.
    • F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.7011 to $0.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F8: The shares are held as follows: 185,062 by AM LLC, 1,168,444 by BV 2014, 77,932 by BV 2014(B), 40,216 by AM BV2014 and 255,639 by MPM OIF.
    • F9: The shares were sold as follows: 5,139 by AM LLC, 32,445 by BV 2014, 2,164 by BV 2014(B), 1,117 by AM BV2014 and 7,098 by MPM OIF.
    • F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.69 to $0.7497 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F11: The shares are held as follows: 179,923 by AM LLC, 1,135,999 by BV 2014, 75,768 by BV 2014(B), 39,099 by AM BV2014 and 248,541 by MPM OIF.

Search

News categories